More on NAMS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.34 |
|
|||
| Open | $25.27 | ||||
| 52 Wk High | $0.00 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $25.43 | ||||
| Day Low | $24.80 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 714,353 | ||||
- NewAmsterdam Pharma (NAMS) call put ratio 1 call to 1 put on 3900 contracts
- NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
- Form 4 NewAmsterdam Pharma Co For: Aug 24 Filed by: Kastelein Johannes Jacob Pieter
- Form 3 NewAmsterdam Pharma Co For: Aug 10 Filed by: Gunning Robert William
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $50 at RBC Capital
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
- NewAmsterdam Pharma to Host Investor Day on August 5, 2026
- EU panel backs NewAmsterdam and Menarini cholesterol drugs
- NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co
Entities mentioned with NAMS
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- SPAC | View Related Stories »
- Jefferies & Co | View Related Stories »
- Earnings | View Related Stories »
- F1 | View Related Stories »
- Show More...
